Last week trial leadership attended the International Conference on Brain Tumor Research and Therapy in Hokkaido, Japan to present updates on GBM AGILE, a global seamless phase 2/3 clinical trial for patients with newly diagnosed and recurrent #glioblastoma. (Left to Right)

Be the first to know what’s next at GCAR!. Subscribe to GCAR’s newsletter for exclusive updates on our cutting-edge platform trials, research initiatives, and the latest developments – delivered straight to your inbox. Join a global community of researchers, clinicians,

Join the effort to successfully treat posttraumatic stress disorder (PTSD) through research. The M-PACT study is investigating how study medications can help people with PTSD. Accepting trial participants at multiple locations in the US with new locations being added. If you or

The M-PACT study is recruiting US military active-duty service members and veterans with PTSD at multiple trial locations. To learn more about trial eligibility, visit: For additional trial information, visit: #PTSD

Did you know that veterans are more likely than civilians to have posttraumatic stress disorder (PTSD)?. PTSD affects approximately 7 out of every 100 veterans. Only two medications - paroxetine and sertraline - are FDA-approved for the treatment of PTSD. While other medications

RT @gliomadoc: Good looking bunch! GBM AGILE has exciting new therapies in the pipeline and is rapidly becoming a repository of massive amo….

GBM AGILE leadership gathering at #ASCO2025 . Trial leadership met to discuss new trial innovations and to advance exciting plans to maximize learning from every patient 🧬🔎 . Since launching in 2019, seven investigational therapies have entered the trial, and sites in six

June marks PTSD Awareness Month - a month dedicated to raising awareness about posttraumatic stress disorder (PTSD), its profound impact on individuals and families, and the importance of seeking help and treatment. In collaboration with the U.S. Department of Defense, GCAR is

That’s a wrap! #ASCO2025. It was wonderful to see and spend time with clinical leadership and collaborators who are partnering with GCAR to advance new #clinicaltrial initiatives in #OvarianCancer, #PancreaticCancer, #BiliaryTractCancer, and #Neurofibromatosis – efficient,

GCAR’s Meredith Buxton and Rob Murray with @aberkenblit, Chief Scientific and Medical Officer, @PanCAN at #ASCO2025

GCAR team and #GBMAGILE investigators at #ASCO2025 with the GBM AGILE trial in progress poster 🧠. To learn more about GBM AGILE, a global adaptive platform trial for patients with newly diagnosed and recurrent #glioblastoma, visit:

As Brain Tumor Awareness Month comes to a close, Dr. Eudocia Lee, Co-PI of the Paxalisib Arm in #GBMAGILE and Director of Clinical Research in Neuro-Oncology at @DanaFarber, reflects on hope fueled by the relentless pursuit of researchers around the world who are working to

New White Paper!.INNOVATION IN ACTION: Data Management Strategies for Master Protocols and Adaptive Platform Trials is here! 📄💡. Master protocols are transforming clinical trials - evaluating multiple therapies under one adaptable framework for faster results, lower costs, and

GBM AGILE Spotlight 🧠✨.Dr. Eudocia Lee, Co-PI Paxalisib Arm GBM AGILE, Director of Clinical Research, Neuro-Oncology, Dana Farber Cancer Institute, and Associate Professor of Neurology, Harvard Medical School, explains the benefits of a platform trial approach to evaluating

RT @aberkenblit: 🧵 Congratulations to @GCAResearch on IMPACT PDAC (Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancr….

RT @PanCAN: @GCAResearch Congratulations @GCAResearch on this exciting milestone! This effort marks a significant step forward in accelerat….

We’re thrilled to unveil the official trial name and logo of GCAR’s forthcoming pancreatic cancer clinical trial! 📣. IMPACT PDAC - Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancreatic Ductal Adenocarcinoma is an investigator-driven, patient-centric